ASTMH 2014

[November 2 – 6, 2014]
American Society of Tropical Medicine and Hygiene, 63rd Annual Meeting
New Orleans, United States

 

 

 

DNDi presented a symposium on human African trypanosomiasis (sleeping sickness), presented new results from an ASMQ clinical study in children, participated in a symposium on Kinetoplastid diseases, and made oral and poster presentations.

DNDi also co-sponsored a side event on Chagas disease.

 

 

Symposium

DNDi Symposium: #164
Towards the elimination of human African trypanosomiasis (HAT)

Date: November 5, 2014

Chair: Jose Ramon Franco, WHO
Co-chair: Crispin Lumbala, PNLTHA

Veerle Lejon, IRD
Advances and challenges in current diagnostics for HAT
Antoine Tarral, Head of HAT Clinical Program, DNDi
New oral treatments for HAT
Wilfried Mutombo, Coordinating investigator, Fexinidazole study for HAT, PNLTHA
Implementation of studies in remote areas in countries with limited regulatory and ethics experience
Jose Ramon Franco Minguell, Department of Control of Neglected Tropical Diseases, WHO
How to achieve HAT elimination with current and new tools

 

MSF Symposium: #153
Transitioning from Vertical to Horizontal: Challenges In Integrating Diagnosis and Treatment of Kinetoplastid Diseases in Essential Health Services

Date: November 5, 2014

Chair: K. Ritmeijer, MSF Holland
Co-chair: François Chappuis, HUG, Geneva

Maria Angeles, MSF, Spain
The right balance between vertical and horizontal approaches to diagnose and treat kinetoplastid diseases: the MSF experience
Crispin Lumbala, Ministry of Health, Kinshasa, DRC
Integration of HAT control into primary healthcare and HAT elimination: achievements and challenges in the DRC
François Chappuis, HUG, Geneva
From a disease-specific to a syndromic diagnostic approach: the cases of visceral leishmaniasis and human African trypanosomiasis

Nathalie Strub-Wourgaft, Medical Director, DNDi
New kinetoplastid diseases treatment that can be easily delivered in rural health posts: when will they be available?
Oral Presentation

Efficacy, Safety and Population Pharmacokinetics of the Artesunate Mefloquine (ASMQ) Fixed Dose Combination versus Artemether Lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in African children

Download Presentation

Date: November 4, 2014

Scientific Session 64: Malaria: Drug Development – New Approaches, Efficacy, Safety and Pharmacology

Sodiomon Sirima1, Bernhards Ogutu2, John Lusingu3, Ali Mtoro4, Zakayo Mrango5, Alphonse Ouedraogo1, Jean Baptiste Yaro1, Kevin Omondi Onyango6, Samwel Gesase3, Ernest Mnkande4, James Samwel Ngocho5, Joelle Vanraes7, Nathalie Strub7, Gwenaelle Carn7

1.) Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso
2.) The Kenya Medical Research Institute, Kisumu, Kenya
3.) National Institute for Medical Research, Korogwe, United Republic of Tanzania
4.) Ifakara Health Institute, Bagamayo, United Republic of Tanzania
5.) National Institute for Medical Research, Kilosa, United Republic of Tanzania
6.) The Centre for Clinical Research- Kenya Medical Research Institute, Nairobi, Kenya
7.) Drugs for Neglected Diseases initiative, Geneva, Switzerland

Drug discovery and development for the treatment and control of filariasis: repurposing emodepside

Download Presentation

Date: November 4, 2014

Scientific Session 108: Filariasis: Clinical
Sabine Specht 1, Charles MacKenzie1, Coralie Martin1, Simon Townson1Robert Don2, Achim Hoerauf1, Ivan Scandale2

1.)Institute for Medical Microbiology, Immunology & Parasitology, University Hospital Bonn, Sigmund Freud Str. 25, 53127 Bonn, Germany
2.) Drugs for Neglected Diseases initiative, Geneva, Switzerland

 

Poster Presentations



The AMFm in Ghana: Factors Associated with Private Retailers: Adherence to the Recommended Retail Price

Download Poster

Date: November 5, 2014

Poster session C
John H. Amuasi*1, Beth Virnig1, Graciela Diap2, The AMFm Independent Evaluation Team3

1.) University of Minnesota School of Public Health, Minneapolis, MN, United States
2.) Drugs for Neglected Diseases initiative, Geneva, Switzerland
3.) Komfo Anokye Teaching Hospital, London School of Hygiene and Tropical Medicine, ICF International, Kumasi, Ghana; London, United Kingdom; Rockville, MD, United States

Oral flubendazole: a potentially useful macrofilaricide
Flubendazole, a potential useful chemotherapeutic agent for treatment and control of filarial infections

Download Poster

Date:
November 3, 2014

Poster session A

Charles D. Mackenzie1, Timothy G. Geary2, Sabine Specht3, Maeghan O’Neill2, Kennan Marsh4, Achim Hoerauf3, Ivan Scandale5, Steven Silber6

1.) Michigan State University, East Lansing, MI, United States
2.) McGill University, Quebec, QC, Canada
3.) Medical University, Bonn, Germany
4.) AbbVie, North Chicago, IL, United States
5.) Drugs for Neglected Diseases initiative, Geneva, Switzerland
6.) JRD, Raritan, NJ, United States

Chagas Side Event

Changing the Face of Chagas Disease: Scaling Up Diagnosis, Treatment and R&D for People Living with Chagas Disease in the Americas
November 3, 2014

More information: ASTMH website